Kidney Allograft Fibrosis, Kidney Transplant Failure and Rejection
Conditions
Keywords
transglutaminase type 2, kidney transplantation, chronic allograft nephropathy, biomarker
Brief summary
The aim of this study is to verify the ability of transglutaminase type 2 to predict rejection or chronic allograft nephropathy of renal allograft. On the basis of biomolecular mechanisms aggravating chronic allograft nephropathy, we eventually expect to develop the remedy to prevent chronic allograft nephropathy after kidney transplantation.
Interventions
DIAGNOSTIC_TESTobservational(urinary biomarker for kidney allograft fibrosis)
After an informed consent is obtained, urine specimens will be collected prospectively before kidney transplantation (if available) and 3rd and 7th day, 1st, 3rd, and 6th month post-transplant. About 35\ 50ml of urine sample is collected from each patient. For each urine specimen, 0.5 ml of a protease inhibitor mixture (5mM 4-(2-animoethyl) benzensulfonyl fluoride hydrolchloride, 2 μM Leupeptin-hemisulfate, and 3.3 mM Sodium azide) is added. To remove urinary sediments including whole cells, large membrane particles, and other debris, urine specimens are centrifuged at a rate of 4000 rpm for 15 minutes at 4 ℃. An aliquot of supernatant is stored at -80 ℃ until use. Urinary biomarkers including transglutaminase 2 are quantified using ELISA or CBA. In addition, urinary exosomes are isolated and analyzed. When a for-cause biopsy is done for some patients, the correlation between biomarkers and pathologic diagnosis will be assessed.
Sponsors
Asan Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* kidney transplant recipients from cadaveric or living donors * kidney transplant recipients who take immunosuppressants regularly * kidney transplant recipients who voluntarily agree to participate in this trial
Exclusion criteria
* multiorgan transplant recipients * kidney transplant recipients with active infection * kidney transplant recipients with alcohol or drug addiction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of level of urinary transglutaminase 2 | 3 days, 7 days, 1 month, 3 months, 6 months post-transplant |
Countries
South Korea
Contacts
Primary ContactSUNG SHIN, MD, PhD
Outcome results
None listed